Investment Rating - The report maintains an "OUTPERFORM" rating for Fuyao Glass Industry Group with a target price of Rmb62.27, down from the previous target of Rmb63.05 [2][6]. Core Views - The company's Q1 2025 results show a revenue of Rmb997 million, a year-on-year increase of 12.2%, and a gross profit of Rmb3.508 billion, reflecting a 7.8% year-on-year growth. The gross profit margin stands at 35.40% [4][15]. - The automotive glass business outperformed the industry, with revenue growth of 12.16% year-on-year and a sales volume increase of 7.84% [5][16]. - The competitive landscape is improving, with capacity expansion supporting market share gains. The company is expected to benefit from declining raw material and freight costs, which will help offset the impact of new capacity ramp-up [6][17]. Financial Summary - Revenue projections for Fuyao Glass are as follows: Rmb39.252 billion for 2024, Rmb45.217 billion for 2025, Rmb51.677 billion for 2026, and Rmb58.540 billion for 2027, indicating a growth rate of 18%, 15%, 14%, and 13% respectively [3][10]. - Net profit estimates are Rmb7.498 billion for 2024, Rmb8.553 billion for 2025, Rmb10.154 billion for 2026, and Rmb11.780 billion for 2027, with growth rates of 33%, 14%, 19%, and 16% respectively [3][10]. - The diluted EPS is projected to be Rmb2.87 for 2024, Rmb3.28 for 2025, Rmb3.89 for 2026, and Rmb4.51 for 2027 [3][10]. Operational Insights - The company has successfully ramped up new capacity, including 1.5 million sets of high-value-added products in the U.S. and additional projects in China, which are expected to enhance overall production efficiency and market presence [6][17]. - The gross profit margin is expected to recover throughout the year, benefiting from lower costs of raw materials and shipping [5][16].

宏观研究 /[Table_Date] 2025.04.20 2025-04-21 全面拆解：各行业面临多少关税 [Table_Authors] 梁中华(分析师) 登记编号 S0880525040019 本报告导读： 美国设计的三类关税措施一一对应财政增收、制造业回流和国家谈判，"想当然"的 希望制造业回流和债务调整。当前中国未受豁免品类最高受关税加征 145%，达到 了 245%，平均而言税率为 121.5%。往后看，美国自身压力会增大，关税的力度可 能出现调整。 投资要点： [Table_Summary] 美国加关税的初衷是"想当然"的促进美国的制造业回流和债务调 整。白宫经济顾问米兰的《全球贸易体系重组指南》里，对"特里 芬悖论"的解释，认为美国提供美元与美债两大储备资产的副作用 是贸易赤字与财政赤字加剧，因而当前使用关税来促进美国的制造 业回流和债务调整，进而改善双赤字问题。 关税的三类措施各有用意 宏 观 研 究 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 宏 观 专 题 021-38676666 刘姜枫(研究助理) 021-38676666 登记编号 S0880123070128 对全 ...

财政节奏：或将加快 [Table_Authors] 侯欢(分析师) ——2025 年 3 月财政数据点评 本报告导读： 3 月财政收支增速边际回升，反映经济阶段性改善。二季度或主要加快 落实存量政策，后续根据需要或继续加码。 投资要点： 登记编号 S0880525040074 研 究 报 告 宏观研究 /[Table_Date] 2025.04.19 2025-04-21 请务必阅读正文之后的免责条款部分 宏 观 研 究 宏 观 专 题 证 券 021-38676666 梁中华(分析师) 021-38676666 登记编号 S0880525040019 [Table_Summary] 狭义收入：增速边际回升。2025 年一季度，全国一般公共预算收入 同比下降 1.1%，其中 3 月当月同比增速 0.3%，相比 1-2 月的增速边 际回升。3 月的财税收入表现反映经济边际改善，或主要与消费补 贴、地产托底政策有关。进一步看，3 月当月，增值税、消费税、企 业所得税收入增速均边际回升；个人所得税收入同比回落，主因基 础因素的扰动；出口退税增速仍然较高，或受 "抢出口"的影响。 此外，非税收入增速边际回落，但仍对财 ...

宏观研究 /[Table_Date] 2025.04.17 2025-04-21 一季度经济中生产、消费、投资全面改善，政策受益板块表现更加强劲，下阶段预 计积极政策会继续逐步发力稳增长。 投资要点： 登记编号 S0880525040087 "开门红"的经济：结构如何 [Table_Authors] 李林芷(分析师) 宏 观 研 究 2025 年一季度经济数据点评 证 券 本报告导读： 研 究 报 告 宏 021-38676666 观 梁中华(分析师) 021-38676666 专 题 请务必阅读正文之后的免责条款部分 | 1. | 一季度"开门红"：多点开花 | 3 | | --- | --- | --- | | 2. | 生产：表现强劲 | 3 | | 3. | 消费：政策利好板块增速高 | 5 | | 4. | 投资：基建投资回升 | 7 | 宏观专题 登记编号 S0880525040019 1. 一季度"开门红"：多点开花 [Table_Summary] 2025 年一季度经济实现"开门红"，GDP 实际同比增长 5.4%，与去 年四季度持平且高于年度增长目标。一方面，促消费、稳地产等政 策叠加春节假 ...

Investment Rating - The report assigns an "Outperform" rating to the company, indicating an expected relative return exceeding the benchmark index by more than 10% over the next 12-18 months [25]. Core Insights - The company is positioned as a unique drilling and energy service provider in Abu Dhabi, being the sole drilling service provider for the Abu Dhabi National Oil Company (ADNOC) [2]. - The company aims for a compound annual growth rate of at least 10% in dividends from FY2024 to FY2028, with dividends expected to reach at least $867 million by FY2025 [3][4]. - The company has a strong profit margin, with an EBITDA margin of approximately 50%, significantly higher than the industry average of around 18% [3]. Summary by Sections Company Overview - The company is focused on supporting ADNOC's goal of achieving a production capacity of 5 million barrels per day by 2027 and increasing natural gas capacity by over 13 billion cubic feet per day by 2030 [2]. - The company has implemented sustainable operations, including hybrid land drilling rigs equipped with battery storage systems to enhance efficiency and reduce fuel consumption [2]. Financial Performance - The company has the highest profit margin in the global oil service sector, with a minimum unlevered internal rate of return of 11-13% for offshore rigs and 10-12% for onshore rigs [3]. - The progressive dividend policy is expected to enhance the company's yield, which is currently competitive at around 4-5% [3]. Project Updates - The company has eight unconventional drilling rigs currently in operation, with plans for further expansion based on project efficiency [4]. - The final investment decision for the second phase of unconventional projects is anticipated by the end of FY2025 or early FY2026 [4]. Growth Strategy - The company plans to increase its rig count from 142 at the end of FY2024 to over 151 by FY2028, supporting its growth trajectory [5].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the Hong Kong healthcare sector, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [1][19][25]. Core Insights - The report highlights President Trump's executive order aimed at lowering prescription drug prices through various measures, including optimizing federal healthcare programs and enhancing regulatory transparency [4][6]. - Key aspects of the executive order include standardizing negotiation timelines for drug prices, promoting competition through accelerated approvals for generics and biosimilars, and increasing transparency in pharmacy benefit manager (PBM) fees [7][4]. Summary by Sections Investment Focus - Companies rated "Outperform" include JD Health, WuXi Biologics, Alibaba Health, and many others, reflecting a positive outlook for the healthcare sector in Hong Kong [1]. Policy Developments - The executive order includes provisions for negotiating drug prices after a uniform timeline of 13 years for both small-molecule and large-molecule drugs, which aims to balance innovation incentives [4][7]. - The order also emphasizes the need for Congressional cooperation for full implementation, suggesting a prolonged timeline for these changes [6]. Market Trends - The report notes the importance of monitoring the evolution of U.S. tariff policies and domestic demand as they relate to the pharmaceutical industry [3]. - It also discusses the recovery of domestic consumption demand policies, which could positively impact the healthcare sector [3].

策略研究 /[Table_Date] 2025.04.20 2025-04-20 当前更似 2020，而非 2018 [Table_Authors] 吴信坤(分析师) 本报告导读： ①类似 2020 年全球疫情，本次美国贸易关税政策或对全球供应链及经济活动造成全 局性冲击。②本次全球大类资产反应也类似 2020 年，权益等风险资产出现大幅波 动，而避险类资产表现更优、黄金价格创下历史新高。③当下宏观政策、科技产业 积极因素正在积累，若类似 2020 年政策空间进一步打开，则资本市场平稳运行提供 宏观保障和基本面支持。 投资要点： 登记编号 S0880525040061 证 券 研 请务必阅读正文之后的免责条款部分 策 略 研 究 海 告 021-38676666 余培仪(分析师) 021-38676666 外 策 略 研 究 究 报 登记编号 S0880525040084 陆嘉瑞(研究助理) 021-38676666 登记编号 S0880125042248 [Table_Summary] 相似点一：全球经贸活动遭全局性冲击。类似 2020 年全球疫情，当 前美国贸易政策或冲击全球供应链和经济活力。2018 年 ...

[Table_Title] 研究报告 Research Report 20 Apr 2025 香港策略 Hong Kong Strategy 等待中美贸易破局及国内政策刺激 Awaiting a Resolution in US-China Trade and Domestic Policy Stimulus 周林泓 Amber Zhou 陈昊飞 Haofei Chen, PhD 李加惠 Jiahui Li, CFA amber.lh.zhou@htisec.com haofei.chen@htisec.com jh.li@htisec.com [Table_yemei1] 观点聚焦 Investment Focus [Table_summary] (Please see APPENDIX 1 for English summary) 上周我们预计市场将进入筑底，因此我们建议投资者逢低加仓，特别是恒生指数19,000-20,000点和上证综指3000- 3100点附近；行业方面，我们建议短期内关注一带一路和内需消费，中长期仍然建议关注科技改革并配以外贸重 塑受益标的。本周市场尚未回落至前低附近，全周恒生指数涨 ...

Investment Rating - The report maintains a NEUTRAL rating for Budweiser Brewing Co APAC with a target price of HK$7.90, down from HK$10.1 [2][12]. Core Insights - The Chinese market is under pressure, with a projected annual sales volume decline of 11.8% in 2024 and a market share contraction of 149 basis points [3][9]. - The company aims to reverse the downward trend in market share through inventory management optimization, channel expansion, and product innovation, although challenges remain [3][9]. - The South Korean market shows strong growth with a 3.6% increase in sales volume and an 8.7% increase in average selling price (ASP) in 2024, alongside a market share expansion of 349 basis points [4][10]. - In India, the high-end product portfolio is expected to see nearly 20% net income growth, with Budweiser's market share doubling over the past five years [4][10]. - The company is undergoing a strategic adjustment period due to leadership changes and external trade challenges, focusing on channel transformation and management efficiency [5][11]. Financial Summary - Revenue for 2024 is projected at US$6.246 billion, with a net profit of US$750 million, reflecting a decline in both revenue and profit compared to previous years [2][8]. - Earnings per share (EPS) for 2025-2027 are forecasted at $0.05, $0.05, and $0.06 respectively, with a price-to-earnings (P/E) ratio of 19x for 2025 [6][12]. - The company has implemented hedging operations for annual costs to manage risks associated with supply chain stability and currency fluctuations [5][11].

Investment Rating - The report initiates coverage with an OUTPERFORM rating, targeting a price of HK$24.20 from the current price of HK$17.70 [1]. Core Insights - Guming Holdings is positioned as a leading 4A (Available, Adorable, Affordable, Addicted) freshly-made beverage brand in China, focusing on the growing demand for fresh, convenient, and cost-effective drinks, particularly in lower-tier cities [1][6]. - The company has established a robust supply chain and utilizes digitalization to enhance operational efficiency, aiming for steady national expansion [3][6]. - Guming is the second-largest freshly-made tea beverage brand in China by GMV, holding a market share of 9.1%, and the largest in the mass market segment with a 17.7% share [1][6]. Company Overview - Guming Holdings operates a network of 9,914 stores across 17 provinces in China, with a significant presence in lower-tier cities, where 41% of its stores are located in rural areas [1][6][29]. - The company has a strong financial outlook, with projected revenues of RMB 10.84 billion, RMB 12.84 billion, and RMB 14.42 billion for 2025, 2026, and 2027, respectively, reflecting growth rates of 23%, 18%, and 12% [1][4]. - Guming's net profit is expected to reach RMB 1.88 billion, RMB 2.19 billion, and RMB 2.38 billion over the same period, with a diluted EPS forecasted to grow from RMB 0.90 in 2025 to RMB 1.14 in 2027 [1][4]. Industry Insights - The freshly-made beverage market in China is experiencing rapid growth, with a compound annual growth rate (CAGR) of 22.5% from 2018 to 2023, significantly outpacing the overall beverage market's growth of 9.4% [2][13]. - The market for freshly-made beverages is projected to reach RMB 11,634 billion by 2028, with a CAGR of 17.6% from 2023 to 2028 [13]. - Freshly-made tea and coffee dominate the market, with their combined market size expected to grow substantially, reflecting changing consumer preferences towards higher quality and fresh products [13][19].